Tabuchi Y, Nakae S, Imanishi K, Nakamura T, Kawasaki H, Ohyama T, Murayama Y, Takiguchi Y, Saitoh Y
Nihon Geka Gakkai Zasshi. 1984 Oct;85(10):1359-69.
Hematogenous recurrence was investigated in 325 cases of colo-rectal cancer. Hematogenous recurrence was confirmed in 34 cases including 25 liver, 5 lung, 2 bone, one brain and one skin recurrence. Most of the cases (28 cases, 82.4%) revealed a single or multiple hematogenous recurrences without showing additional other types of recurrence. Histological examination of cancer lesions indicated that patients with the findings consisting of moderate and/or high grade of vein invasion (v2-3), subserosal and extramural vein invasion with node metastasis showed high recurrent rate. One and two year survival rate of the patients treated with MF-MF' adjuvant chemotherapy was greater those the patients with F-F' chemotherapy or those without chemotherapy. However, 3-, 4- and 5- year survival rate did not show significant difference among 3 therapeutic groups. The analysis of survival curves also indicated no significant difference among 3 therapeutic groups. These results may suggest that hematogenous recurrence is derived from pre- and/or intra-operative micrometastasis or transplantation of cancer cells, that patients with the above mentioned histological evidence must be clinically treated as a high risk group for recurrence and that MF-MF' adjuvant chemotherapy can be effective in lowering the recurrence rate during the first one or two years after operation.
对325例结直肠癌患者的血行转移复发情况进行了研究。确诊有34例发生血行转移复发,其中25例为肝转移、5例为肺转移、2例为骨转移、1例为脑转移、1例为皮肤转移。大多数病例(28例,82.4%)表现为单发或多发血行转移复发,未出现其他类型的复发。对癌灶进行组织学检查表明,出现中度和/或高度静脉侵犯(v2 - 3)、浆膜下和壁外静脉侵犯并伴有淋巴结转移的患者复发率较高。接受MF - MF'辅助化疗的患者1年和2年生存率高于接受F - F'化疗的患者或未接受化疗的患者。然而,3年、4年和5年生存率在3个治疗组之间没有显著差异。生存曲线分析也表明3个治疗组之间没有显著差异。这些结果可能提示,血行转移复发源于术前和/或术中的微转移或癌细胞移植,具有上述组织学证据的患者在临床上必须被视为复发高危组,并且MF - MF'辅助化疗在降低术后头一两年的复发率方面可能有效。